Filing Details
- Accession Number:
- 0001127602-21-015257
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-04 13:00:00
- Reporting Period:
- 2021-05-03
- Accepted Time:
- 2021-05-04 16:56:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1682852 | Moderna Inc. | MRNA | Biological Products, (No Disgnostic Substances) (2836) | 813467528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1690927 | Zvi Tal Zaks | C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-05-03 | 5,000 | $12.21 | 5,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-05-03 | 271 | $183.42 | 4,729 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-05-03 | 800 | $184.77 | 3,929 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-05-03 | 1,089 | $186.04 | 2,840 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-05-03 | 1,924 | $187.10 | 916 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-05-03 | 916 | $188.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-05-03 | 5,000 | $0.00 | 5,000 | $12.21 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
141,282 | 2027-10-03 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $183.19 to $183.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.21 to $185.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $185.54 to $186.54 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $186.65 to $187.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $187.69 to $188.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).